Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.

Autor:	Girard B; Pediatric Neurology Unit, Children's Hospital, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France., Bonnemains C; Pediatric Metabolic Unit, Children's Hospital, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France., Schmitt E; Pediatric Neurology Unit, Children's Hospital, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France/EA 3450 DeVAH, Faculty of Medicine, University of Lorraine, Vandoeuvre-lès-Nancy, France., Raffo E; Diagnostic and Therapeutic Neuroradiology Department, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France., Bilbault C; Pediatric Neurology Unit, Children's Hospital, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France.
Jazyk:	angličtina
Zdroj:	Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2017 Jan; Vol. 23 (1), pp. 119-122. Date of Electronic Publication: 2016 Jul 11.
DOI:	10.1177/1352458516646087
Abstrakt:	Background: Metabolic and inflammatory conditions may lead to neurological disorders. Neuromyelitis optica spectrum disorders (NMOSDs) refer to a rare group of demyelinating diseases of the central nervous system which essentially involve the optic nerves and spinal cord. Methods: We report a case of biotinidase deficiency (BD) initially misdiagnosed as NMOSD in a pediatric patient. Results: An 8-year-old girl was initially diagnosed with NMOSD on the basis of optic neuritis (ON) associated with three episodes of longitudinally extensive transverse myelitis (LETM). Intravenous high-dose corticosteroids were effective during the first two episodes of LETM. The third acute episode which resulted in tetraplegia, respiratory distress, and blindness was refractory to corticosteroids, plasmapheresis, and rituximab. The unusual clinical course and persistent high levels of plasma and cerebrospinal fluid (CSF) lactate led to additional metabolic investigations being performed. Acylcarnitine profile revealed increased C5-OH acylcarnitine suggestive of BD. Diagnosis was confirmed by direct assessment of plasma enzyme activity (quantified as 5% of the control value). Genetic analysis revealed two mutations, c.643C>T (p.L215F) and c.1612C>T (p.R538C), in the BTD gene (3p25). Dramatic clinical improvement occurred after long-term oral biotin treatment. Conclusion: BD is a treatable condition that may closely mimic the neurological findings of LETM and NMOSD.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu